Historial de carrera de Ira Wallis
Antiguos cargos conocidos de Ira Wallis.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Consejero General | - | 03/02/2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | Consejero General | 01/05/2001 | 01/01/2003 |
| CERUS CORPORATION | Director/Miembro de la Junta | 01/07/1996 | 01/04/2001 |
| Consejero General | 01/07/1996 | 01/04/2001 | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Consejero General | 01/01/1990 | 01/01/1996 |
| Sandoz Pharmaceuticals Corp. | Consejero General | 01/01/1987 | 01/01/1989 |
Formación de Ira Wallis.
| American International College | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| General Counsel | 5 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CERUS CORPORATION | Health Technology |
| Empresas privadas | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Sandoz Pharmaceuticals Corp. |
- Bolsa de valores
- Insiders
- Ira Wallis
- Experiencia
